Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease

Alzheimer's Disease Clinical Trial

— MAL  

Official title:

Evaluating the Impact of Physical Exercise on Mild Alzheimer's Disease in a Randomized Clinical Trial: Quantification With 18F -FDG and 11C- AcAc PET Imaging

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02708485
• Other study ID #: 09-043
• Status: Completed
• Phase: N/A
• Start date: April 2009
• Est. completion date: July 2017

Study information

• Verified date: July 2017
• Source: Université de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effect of a 3-month walking program on brain energy metabolism in patient with mild Alzheimer's disease (AD). Two groups of sedentary patients with mild AD are followed and compared over a 3-month period of time: Control (non-active) and walking (from 15 to 45 minutes of exercise on a treadmill, 3 times a week for 12 weeks) groups. All the participants are evaluated on their cognition, brain volumes (MRI) and brain fuel consumption (PET scan with 18-FDG and 11C-AcAc) at the beginning and at the end of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: July 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of mild Alzheimer's disease (NINCDS-ADRDA criteria)

• Taking cholinesterase inhibitors

• Sedentary

• Ability to do physical exercise

Exclusion Criteria:

• Parkinson disease

• Down syndrome

• Epilepsy or concussion

• Drug or alcohol abuse

• Past psychiatric history

• Vitamin B12 Deficiency

• Uncontrolled diabetes or thyroid function

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Other:
• Physical exercise
A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).

Locations

Country	Name	City	State
Canada	Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)	Sherbrooke	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Université de Sherbrooke

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brain Glucose Consumption	Brain glucose uptake (umol/100g/min) using 18F-FDG PET imaging	3 months
Primary	Brain Acetoacetate Consumption	Brain acetoacetate uptake (umol/100g/min) using 11C-AcAc PET imaging	3 months